Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Rubella virus vaccine | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Uprifosbuvir. |
| Bacillus calmette-guerin substrain tice live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Uprifosbuvir. |
| Bacillus calmette-guerin substrain connaught live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Uprifosbuvir. |
| Yellow fever vaccine | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Uprifosbuvir. |
| Anthrax vaccine | The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Uprifosbuvir. |
| Typhoid Vaccine Live | The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Uprifosbuvir. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Uprifosbuvir. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Uprifosbuvir. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Uprifosbuvir. |
| Adenovirus type 7 vaccine live | The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Uprifosbuvir. |
| Varicella zoster vaccine (live/attenuated) | The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Uprifosbuvir. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Uprifosbuvir. |
| Chikungunya vaccine (live, attenuated) | The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Uprifosbuvir. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Uprifosbuvir. |